论文部分内容阅读
肥胖是一个全球流行性疾病,随着肥胖发病率的升高,肥胖相关性疾病的发生率亦相伴升高,尤其是未能控制的高血压。生活方式干预是肥胖相关性高血压管理的基石,但却很难坚持,常需应用降压药物使血压达标。利尿剂、肾素-血管紧张素系统抑制剂和二氢吡啶类钙通道阻滞剂常被作为血压控制用药三重奏,在其基础上还可联合盐皮质激素受体拮抗剂和/或双α/β受体阻滞剂。尽管现在已有多种类别的降血压药物,然而约50%的高血压患者的血压治疗仍未达到标准。一些降低血压的新药和侵入性治疗方法正在蓬勃发展,具备有效管理肥胖相关性高血压的前景。
Obesity is a global epidemic with an associated increase in the incidence of obesity-related diseases as obesity increases, especially in uncontrolled hypertension. Lifestyle intervention is the cornerstone of obesity-related hypertension management, but it is difficult to adhere to, often requiring antihypertensive drugs to blood pressure compliance. Diuretics, renin - angiotensin system inhibitors and dihydropyridine calcium channel blockers are often used as blood pressure control trio of medication, in combination with mineralocorticoid receptor antagonists and / or dual α / Beta blockers. Although many classes of antihypertensive drugs are available, about 50% of those with essential hypertension have not yet achieved their standard of care. Some new blood pressure lowering drugs and invasive therapies are booming and have the potential to effectively manage obesity-related hypertension.